Lisa O'BRien

Lisa O'BRien

Auto-generated profile, based on publicly available information

Lisa O'BRien

Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Clinical Therapeutics
Verified
Journal Article
Closed access
BBBenjamin Bar-Oz
Benjamin Bar-Oz
TEThomas Einarson
Thomas Einarson
AEAdrienne Einarson
Adrienne Einarson
RBRadinka Boskovic
Radinka Boskovic
LOLisa O'Brien
Lisa O'Brien
GKGideon Koren
Gideon Koren

28 April 2009 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SGSimerpal K Gill
Simerpal K Gill
LOLisa O'BRien
Lisa O'BRien
TEThomas R Einarson
Thomas R Einarson
GKGideon Koren
Gideon Koren
Heartburn and acid reflux are common medical disorders in pregnancy and can result in serious discomfort and complications. Furthermore, some pregnant women also experience more severe gastrointestinal conditions, such as Helicobacter pylori infections, peptic ulcers, and Zollinger–Ellison syndrome. To allow the use of proton pump inhibitors (PPIs) in pregnancy, the fetal safety of this drug class must be established. The aim of this study is to determine the fetal safety of PPIs during early pregnancy through systematic literature review. All original research assessing the safety of PPIs in pregnancy was sought from inception to July 2008. Two independent reviewers identified articles, compared results, and settled differences through consensus. The Downs–Black scale was used to assess quality. Data assessed included congenital malformations, spontaneous abortions, and preterm delivery. A random effects meta-analysis combined the results from included studies. Of the 60 articles identified, 7 met our inclusion criteria. Using data from 134,940 patients, including 1,530 exposed and 133,410 not exposed to PPIs, the overall odds ratio (OR) for major malformations was 1.12 (95% confidence interval, CI: 0.86–1.45). Further analysis revealed no increased risk for spontaneous abortions (OR=1.29, 95% CI: 0.84–1.97); similarly, there was no increased risk for preterm delivery (OR=1.13, 95% CI: 0.96–1.33). In the secondary analysis of 1,341 exposed and 120,137 not exposed to omeprazole alone, the OR and 95% CI for major malformations were 1.17 and 0.90–1.53, respectively. On the basis of these results, PPIs are not associated with an increased risk for major congenital birth defects, spontaneous abortions, or preterm delivery. The narrow range of 95% CIs is further reassuring, suggesting that PPIs can be safely used in pregnancy.

1 April 2009 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
BBBenjamin Bar-Oz
Benjamin Bar-Oz
MMMyla E. Moretti
Myla E. Moretti
RBRadinka Boskovic
Radinka Boskovic
LOLisa O’bRien
Lisa O’bRien
GKGideon Koren
Gideon Koren

1 January 2005 in Pediatric Drugs
Verified
Journal Article
Closed access
PDF file
LOLisa O’brien
Lisa O’brien
ATAnna Taddio
Anna Taddio
DLDorothy A. Lyszkiewicz
Dorothy A. Lyszkiewicz
GKGideon Koren
Gideon Koren

3 December 2008 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
SGSimerpal Kaur Gill
Simerpal Kaur Gill
LOLisa O’brien
Lisa O’brien
GKGideon Koren
Gideon Koren

1 December 2009 in Pain
Verified
Journal Article
Closed access
ATAnna Taddio
Anna Taddio
LOLisa O’bRien
Lisa O’bRien
MIMoshe Ipp
Moshe Ipp
DSDerek Stephens
Derek Stephens
MGMorton Goldbach
Morton Goldbach
GKGideon Koren
Gideon Koren
We tested the reliability and validity of observer-rated pain in infants undergoing immunization using the visual analog scale (VAS). Pain was assessed in real time and later, from videotapes, in 120 1-year-old infants participating in a double-blind randomized controlled trial of amethocaine vs. placebo. Altogether, 2 (1 physician, 1 non-physician) of 4 raters [2 physicians, 2 non-physicians (nurse and graduate student)] independently assessed baseline and vaccine injection pain using a 100mm unmarked VAS line. Intra- and inter-rater reliability, assessed using the intra-class correlation coefficient (ICC), ranged from 0.69 to 0.91 and 0.55 to 0.97, respectively. Bland-Altman plots demonstrated no evidence of bias between real time and video assessments. When scores were dichotomized into 2 groups (no pain and pain) using a cut-off of >or=30mm, intra-rater reliability ranged from 0.35 to 0.92. The percent of scores deviating by >20mm was 4.5-14.29%. Criterion validity was demonstrated by correlations between the VAS and Modified Behavioural Pain Scale, a validated observational measure; (rho: 0.81-0.94). Injection scores were lower in the amethocaine group, when comparing difference (baseline-injection) or dichotomized scores; significance (p<0.036) was achieved for non-physician scores, but not physician scores. Together, these results provide initial support for the VAS as an outcome measure for acute procedural pain in infants. However, different conclusions may be reached about the effectiveness of analgesic interventions depending on the rater. Sources of variability include use of multiple raters, rater focus (procedure vs. child) and experience level.